THE TAPE
RLAY · Biotechnology · $3.8B

Relay Therapeutics, Inc. Common Stock

$17.27▼ −4.53%
Last close
Relative strength
95RS
of 99, against every stock▲ +6 on the month
Powering up
Unconfirmed
+16.2%
six months against Biotechnology
52-week range
−18.8%
from the high
$6.17$21.27
Setup
blue skyforming
−18.8%
against the pivot at $21.27
No report date on the calendar.
Growth WEAKProof PENDING
Quarter to Sep 30
11/16 O 17.81 H 18.07 L 17.22 Vol 1.7M
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

All four are in order, fastest above slowest — every timeframe pointing the same way.

RS95
vs pivot−18.81%
Tightening0.80×
Dry-up1.26×
Up/down vol-0.23
From high19%
forming4 of 9checks
Powering up
Support and resistance
Support below
$16.76
-3.0% · tested 5× · last 7 sessions ago
Resistance above
$17.88
+3.5% · tested 8× · last 16 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 12.6 weeks and fell 24% from its ceiling at its deepest. The pivot is $21.27, and the stock closed 18.8% below it. Its relative strength rating is 95.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
+3.1%
Three months against its industry
-10.7%
Six months against its industry
+16.2%

Read against an equal-weighted index of Biotechnology, which is +22.6% against the S&P 500 over six months Partly aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 5.8% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$10.3M
Operating margin
-3094.6%
Net margin
-2837.0%
Free cash flow
$-214.0M
-5.7% of market cap
Price to sales
365.7×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 4
Key takeaway
Shrinking and burning cash: the quarter weakens the case.
Revenue
—
-100.0% QoQ · — YoY
Gross margin
—
Net income
−$81.7M
Loss
Free cash flow
−$63.9M
Burning · 2q runway

What the numbers say

  • Weak: Revenue -100.0% on the quarter (no year-earlier quarter on file)
  • Weak: Net loss $82M, narrower than $84M last quarter
  • Weak: Burning cash: operating cash flow -$64M, free cash flow -$64M, worse than -$54M last quarter · 2 quarters of cash at this burn
  • Weak: Share count +27.1% in a year: dilution
  • Good: Net cash $124M · cash $124M
Revenue by quarter
Free cash flow
Net income
shares +27.1% in a year · net cash $124.2M

What is not obvious

  • Weak: Stock compensation $10M added back against negative operating cash flow
Final read
Growth: WEAK · Economic proof: PENDING
Key question: What turns the cash flow positive?
The next test is revenue growth: revenue -100.0% on the quarter (no year-earlier quarter on file).

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 3 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 bought new, 2 added, 1 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-13
-8.3%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-10
+9.6%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-07
+9.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Closed below its 20- and 50-day on heavy volumeTape · 2026-11-06
below 20d & 50d on 1.8x volume at 17.00
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
GappedTape · 2026-11-06
-5.7%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Reported resultsFiling · 2026-11-05
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Earnings comingEvent · 2026-11-03
reports 2026-11-04
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
GappedTape · 2026-11-03
-5.8%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news

No headlines for this company in the last couple of weeks.

Insiders
Bought on the open market
0
Sold on the open market
25
$127,749,315 total

Sold: Rahmer Peter, Bergstrom Donald A, Catinazzo Thomas, Patel Sanjiv, SVF Pauling (Cayman) Ltd.

Not counted above: 6 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-10-28 Rahmer Peter · See remarkssell753$14,021
2026-10-28 Bergstrom Donald A · President, R&Dsell2,252$41,932
2026-10-28 Catinazzo Thomas · Chief Financial Officersell1,469$27,353
2026-10-07 Patel Sanjiv · President and CEO, Directorsell48,199$872,402
2026-10-06 Catinazzo Thomas · Chief Financial Officersell17,511$325,354
2026-10-06 Catinazzo Thomas · Chief Financial Officersell206$3,968
2026-09-08 Bergstrom Donald A · President, R&Dsell8,530$161,814
2026-09-08 Catinazzo Thomas · Chief Financial Officersell17,717$335,560

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What lines up

4 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy3
Buy9
Hold0
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

Checking your subscription…

X-ray
13w · 24%

The most recent of 2 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Relay Therapeutics, Inc. Common Stock (RLAY) — The Tape